Researchers at Kaist have developed the first technology to selectively acetylate specific RNA molecules inside living cells using the CRISPR-Cas13 system. This breakthrough enables precise, programmable control of RNA function and marks a major step forward in RNA-based therapeutics and gene regulation research.
Read on